Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Waldenstrom Macroglobulinemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Lymphoplasmacytic Lymphoma (64
)
Lymphoplasmacytic Lymphoma (64
)
›
Associations
(62)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
acalabrutinib
Sensitive: A2 - Guideline
acalabrutinib
Sensitive
:
A2
acalabrutinib
Sensitive: A2 - Guideline
acalabrutinib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: A2 - Guideline
rituximab + ixazomib
Sensitive
:
A2
rituximab + ixazomib
Sensitive: A2 - Guideline
rituximab + ixazomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
fludarabine oral
Sensitive: A2 - Guideline
fludarabine oral
Sensitive
:
A2
fludarabine oral
Sensitive: A2 - Guideline
fludarabine oral
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
cladribine
Sensitive: A2 - Guideline
cladribine
Sensitive
:
A2
cladribine
Sensitive: A2 - Guideline
cladribine
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
rituximab + bortezomib
Sensitive: A2 - Guideline
rituximab + bortezomib
Sensitive
:
A2
rituximab + bortezomib
Sensitive: A2 - Guideline
rituximab + bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
everolimus
Sensitive: A2 - Guideline
everolimus
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
ofatumumab
Sensitive: A2 - Guideline
ofatumumab
Sensitive
:
A2
ofatumumab
Sensitive: A2 - Guideline
ofatumumab
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
CLR 131
Sensitive: B - Late Trials
CLR 131
Sensitive
:
B
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 wild-type
Waldenstrom Macroglobulinemia
MYD88 wild-type
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 mutation
Waldenstrom Macroglobulinemia
MYD88 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
CXCR4 mutation
Waldenstrom Macroglobulinemia
CXCR4 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 mutation
Waldenstrom Macroglobulinemia
MYD88 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive: C2 – Inclusion Criteria
ibrutinib
Sensitive
:
C2
ibrutinib
Sensitive: C2 – Inclusion Criteria
ibrutinib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
CXCR4 mutation
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
rituximab + ixazomib
Sensitive
:
C2
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
rituximab + ixazomib
Sensitive
:
C2
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
rituximab + ixazomib
Sensitive
:
C2
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
rituximab + ixazomib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
CXCR4 mutation
Waldenstrom Macroglobulinemia
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib + BMS-936564
Sensitive: C2 – Inclusion Criteria
ibrutinib + BMS-936564
Sensitive
:
C2
ibrutinib + BMS-936564
Sensitive: C2 – Inclusion Criteria
ibrutinib + BMS-936564
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login